The nanotechnological approach for nasal delivery of peptide drugs: a comprehensive review

References

• Agu, R.U., 2016. Challenges in nasal drug absorption: how far have we come? Therapeutic delivery, 7 (7), 495–510.
   PubMedGoogle Scholar
• Ahmad, M.U., Ali, S.M., and Ahmad, I., 2012. Applications of nanotechnology in pharmaceutical development. In: M.U. Ahmad, ed. Lipids in Nanotechnology. Libertyville (IL): Elsevier, 171–190.
   Google Scholar
• Akashi, M. and Ikizawa, K., 2007. Biodegradable nanoparticle having cedar pollen T-cell recognizable epitope peptide immobilized thereon or encapsulated therein. Pharmaceuticals. US Patent No. 20090156480A1. In: Section title: pharmaceuticals (US20090156480A1).
   Google Scholar
• al Bakri, W., et al., 2018. Overview of intranasally delivered peptides: key considerations for pharmaceutical development. Expert opinion on drug delivery, 15 (10), 991–1005.
   PubMed Web of Science ®Google Scholar
• Amirnasr, M., et al., 2016. Immunization against HTLV-I with chitosan and tri-methylchitosan nanoparticles loaded with recombinant env23 and env13 antigens of envelope protein gp46. Microbial pathogenesis, 97, 38–44.
   PubMed Web of Science ®Google Scholar
• Aneja, R., et al., 2019. Pharmacokinetic stability of macrocyclic peptide triazole HIV-1 inactivators alone and in liposomes. Journal of peptide science, 25 (4), e3155.
   PubMed Web of Science ®Google Scholar
• Ariën, A., and Stoffels, P., 2016. History: potential, challenges, and future development in nanopharmaceutical research and industry. In: J. Cornier, A. Owen, A. Kwade, and M. van de Voorde, eds. Pharmaceutical nanotechnology: innovation and production. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 1–16.
   Google Scholar
• Avila, C.L., et al., 2017. Lessons learned from protein aggregation: toward technological and biomedical applications. Biophysical reviews, 9 (5), 501–515.
   PubMedGoogle Scholar
• Azegami, T., et al., 2018. Intranasal vaccination against angiotensin II type 1 receptor and pneumococcal surface protein A attenuates hypertension and pneumococcal infection in rodents. Journal of hypertension, 36 (2), 387–394.
   PubMed Web of Science ®Google Scholar
• Azegami, T., et al., 2017. Nanogel-based nasal ghrelin vaccine prevents obesity. Mucosal immunology, 10 (5), 1351–1360.
   PubMed Web of Science ®Google Scholar
• Barros, C.D., et al., 2021. Quality by design approach for the development of liposome carrying ghrelin for intranasal administration. Pharmaceutics, 13 (5), 686.
   PubMed Web of Science ®Google Scholar
• Baxter, R.P., et al., 2018. Live attenuated influenza vaccination before 3 years of age and subsequent development of Asthma: A 14-year follow-up study. The pediatric infectious disease journal, 37 (5), 383–386.
   PubMed Web of Science ®Google Scholar
• Behzadi, M., et al., 2021. Iron nanoparticles as novel vaccine adjuvants. European journal of pharmaceutical sciences, 159, 105718.
   PubMed Web of Science ®Google Scholar
• Ben-Yehuda, A., et al., 2003. Immunogenicity and safety of a novel IL-2-supplemented liposomal influenza vaccine (INFLUSOME-VAC) in nursing-home residents. Vaccine, 21 (23), 3169–3178.
   PubMed Web of Science ®Google Scholar
• Berrill, A., Biddlecombe, J., and Bracewell, D., 2011. Product quality during manufacture and supply. In: C.F. van der Walle, ed. Peptide and protein delivery. London, UK: Elsevier, 313–339.
   Google Scholar
• Bhatia, S., 2017. Nanotechnology in drug delivery: fundamentals, design, and applications. 1st ed. New York, NY: Apple Academic Press.
   Google Scholar
• Bhumkar, D.R., et al., 2007. Chitosan reduced gold nanoparticles as novel carriers for transmucosal delivery of insulin. Pharmaceutical research, 24 (8), 1415–1426.
   PubMed Web of Science ®Google Scholar
• Boge, L., et al., 2018. Freeze-dried and re-hydrated liquid crystalline nanoparticles stabilized with disaccharides for drug-delivery of the plectasin derivative AP114 antimicrobial peptide. Journal of colloid and interface science, 522, 126–135.
   PubMed Web of Science ®Google Scholar
• Borrajo, M.L., and Alonso, M.J., 2022. Using nanotechnology to deliver biomolecules from nose to brain: peptides, proteins, monoclonal antibodies and RNA. Drug delivery and translational research, 12 (4), 819–862.
   Web of Science ®Google Scholar
• Casal Alvarez, J. I., and Bartolomé Conde, R. Á., 2020. US2021363224A1 IL13Ra2 Peptide and its uses.
   Google Scholar
• Chan, J., Rajadas, J., and Steinman, L., 2021. WO2021195580A1 Prevention and treatment of coronavirus-associated diseases using an apelin peptide and formulations thereof.
   Google Scholar
• Chatterjee, B., et al., 2019. Targeted drug delivery to the brain via intranasal nanoemulsion: available proof of concept and existing challenges. International journal of pharmaceutics, 565, 258–268.
   PubMed Web of Science ®Google Scholar
• Cho, H.-J., et al., 2011. Evaluation of protein stability and in vitro permeation of lyophilized polysaccharides-based microparticles for intranasal protein delivery. International journal of pharmaceutics, 416 (1), 77–84.
   PubMed Web of Science ®Google Scholar
• Cho, W., et al., 2015. Design of salmon calcitonin particles for nasal delivery using spray-drying and novel supercritical fluid-assisted spray-drying processes. International journal of pharmaceutics, 478 (1), 288–296.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov, 2011a. A study of oxytocin in children and adolescents with autistic disorder. University of North Carolina, Chapel Hill. United States, No. NCT01308749.
   Google Scholar
• ClinicalTrials.gov, 2011b. Does acute oxytocin administration enhance social cognition in individuals with schizophrenia? VA Greater Los Angeles Healthcare System. United States, No. NCT01312272.
   Google Scholar
• ClinicalTrials.gov, 2013. Nasally and subcutaneously administered teriparatide in healthy volunteers. Nottingham University Hospitals NHS Trust; Critical Pharmaceuticals. United Kingdom, No. NCT01913834.
   Google Scholar
• ClinicalTrials.gov, 2015a. A study in participants with type 2 diabetes mellitus (AWARD-3). Eli Lilly and Company. Germany, No. NCT03339453.
   Google Scholar
• ClinicalTrials.gov, 2015b. Memory aid by intranasal insulin in diabetes (MemAID). Beth Israel Deaconess Medical Center. United States, No. NCT02415556.
   Google Scholar
• ClinicalTrials.gov, 2017a. PINIT study: primary intranasal insulin trial. München, Technische Universität. Germany, No. NCT03182322.
   Google Scholar
• ClinicalTrials.gov, 2017b. Intranasal vasopressin treatment in children with autism. Stanford University. United States, No. NCT03204786.
   Google Scholar
• ClinicalTrials.gov, 2018. Intranasal glucagon and energy balance. University Health Network, Toronto. Canada, No. NCT03650582.
   Google Scholar
• Colombo, M., et al., 2018. Kaempferol-loaded mucoadhesive nanoemulsion for intranasal administration reduces glioma growth in vitro. International journal of pharmaceutics, 543 (1-2), 214–223.
   PubMed Web of Science ®Google Scholar
• Cornier, J., et al., 2016. Characterization methods: physical and chemical characterization techniques. In: J. Cornier, A. Owen, A. Kwade, and M. van de Voorde, eds. Pharmaceutical nanotechnology: innovation and production. Weinheim, DE: Wiley-VCH Verlag, 135–156.
   Google Scholar
• de Souza Von Zuben, E., et al., 2021. Insulin-loaded liposomes functionalized with cell-penetrating peptides: influence on drug release and permeation through porcine nasal mucosa. Colloids and surfaces A: Physicochemical and engineering aspects, 622, 126624.
   Web of Science ®Google Scholar
• Dehghan, S., et al., 2018. Preparation, characterization and immunological evaluation of alginate nanoparticles loaded with whole inactivated influenza virus: dry powder formulation for nasal immunization in rabbits. Microbial pathogenesis, 115, 74–85.
   PubMed Web of Science ®Google Scholar
• Dhakal, S., et al., 2018. Liposomal nanoparticle-based conserved peptide influenza vaccine and monosodium urate crystal adjuvant elicit protective immune response in pigs. International journal of nanomedicine, 13, 6699–6715.
   PubMed Web of Science ®Google Scholar
• Dolberg, A.M., and Reichl, S., 2018. Expression analysis of human solute carrier (SLC) family transporters in nasal mucosa and RPMI 2650 cells. European journal of pharmaceutical sciences, 123, 277–294.
   PubMed Web of Science ®Google Scholar
• Dreijer-van der Glas, S., and Hafner, A., 2015. Nose. In: Y. Bouwman-Boer; V. Fenton-May; P. Le Brun, eds. Practical pharmaceutics. Cham, CH: Springer, 139–152.
   Google Scholar
• Dumont, C., et al., 2018. Lipid-based nanosuspensions for oral delivery of peptides, a critical review. International journal of pharmaceutics, 541 (1-2), 117–135.
   PubMed Web of Science ®Google Scholar
• Edwards, P. J., and LaPlante, S. R., 2011. Peptides as leads f or drug discovery. In: M. Castanho and N. Santos, eds. Peptide drug discovery and development. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 1–55.
   Google Scholar
• El‐Kamary, S.S., et al., 2010. Adjuvanted intranasal Norwalk virus‐like particle vaccine elicits antibodies and antibody‐secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. The journal of infectious diseases, 202 (11), 1649–1658.
   PubMed Web of Science ®Google Scholar
• El-Mekawy, R.E. and Jassas, R.S., 2017. Recent trends in smart and flexible three-dimensional cross-linked polymers: synthesis of chitosan-ZnO nanocomposite hydrogels for insulin drug delivery. MedChemComm, 8 (5), 897–906.
   PubMed Web of Science ®Google Scholar
• Emami, A., et al., 2018. Toxicology evaluation of drugs administered via uncommon routes: intranasal, intraocular, intrathecal/intraspinal, and intra-articular. International journal of toxicology, 37 (1), 4–27.
   PubMed Web of Science ®Google Scholar
• Fahimirad, S., et al., 2021. Antimicrobial activity, stability and wound healing performances of chitosan nanoparticles loaded recombinant LL37 antimicrobial peptide. International journal of peptide research and therapeutics, 27 (4), 2505–2515.
   Web of Science ®Google Scholar
• Feng, Y., et al., 2018. An update on the role of nanovehicles in nose-to-brain drug delivery. Drug discovery today, 23 (5), 1079–1088.
   PubMed Web of Science ®Google Scholar
• Ferreira, L.M.B., et al., 2018. Exploiting supramolecular interactions to produce bevacizumab-loaded nanoparticles for potential mucosal delivery. European polymer journal, 103, 238–250.
   Web of Science ®Google Scholar
• Fonseca, F.N., et al., 2015. Mucoadhesive amphiphilic methacrylic copolymer-functionalized poly(ε-caprolactone) nanocapsules for nose-to-brain delivery of olanzapine. Journal of biomedical nanotechnology, 11 (8), 1472–1481.
   PubMed Web of Science ®Google Scholar
• Frère, Y., Danicher, L., and Muller, S., 2013. Peptide nanostructured conjugates for therapeutics. In: C. Alemán, A. Bianco, and M. Venanzi, eds. Peptide materials. Chichester, UK: John Wiley & Sons, 385–415.
   Google Scholar
• Garcia-Fuentes, M., Torres, D., and Alonso, M., 2005. New surface-modified lipid nanoparticles as delivery vehicles for salmon calcitonin. International journal of pharmaceutics, 296 (1–2), 122–132.
   PubMed Web of Science ®Google Scholar
• Gaudana, R., et al., 2011. Encapsulation of protein-polysaccharide HIP complex in polymeric nanoparticles. Journal of drug delivery, 2011, 458127–458128.
   Google Scholar
• Gebril, A.M., et al., 2014. Assessment of the antigen-specific antibody response induced by mucosal administration of a GnRH conjugate entrapped in lipid nanoparticles. Nanomedicine: nanotechnology, biology, and medicine, 10 (5), 971–e979.
   PubMed Web of Science ®Google Scholar
• Gill, N., Wlodarska, M., and Finlay, B.B., 2010. The future of mucosal immunology: studying an integrated system-wide organ. Nature immunology, 11 (7), 558–560.
   PubMed Web of Science ®Google Scholar
• Godfrey, L., et al., 2018. Nanoparticulate peptide delivery exclusively to the brain produces tolerance free analgesia. Journal of controlled release, 270, 135–144.
   PubMed Web of Science ®Google Scholar
• Griesser, J., et al., 2017. Hydrophobic ion pairing: key to highly payloaded self-emulsifying peptide drug delivery systems. International journal of pharmaceutics, 520 (1–2), 267–274.
   PubMed Web of Science ®Google Scholar
• Guo, H., et al., 2021. Biodegradable nano-porous Mn3O4 with sustainable release for improving the stability and bioactivity of peptide RVPSL. LWT, 152, 112384.
   Web of Science ®Google Scholar
• Hu, C.M.J., and Yang, H.C., 2021. A vaccine comprising a nanoparticle encapsulating epitopes and adjuvant, a method for manufacturing the same, and a method for neutralizing virus infection. Patent No. TW202108169A.
   Google Scholar
• Huang, Y., et al., 2020. RP1, a RAGE antagonist peptide, can improve memory impairment and reduce Aβ plaque load in the APP/PS1 mouse model of Alzheimer's disease. Neuropharmacology, 180, 108304.
   PubMed Web of Science ®Google Scholar
• Illum, L., 2015. Intranasal delivery to the central nervous system. In: L. Di and E.H. Kerns, eds. Blood-brain barrier in drug discovery. Hoboken, NJ: John Wiley & Sons, 535–565.
   Google Scholar
• Ingrole, R.S.J., et al., 2021. M2e conjugated gold nanoparticle influenza vaccine displays thermal stability at elevated temperatures and confers protection to ferrets. Vaccine, 39 (34), 4800–4809.
   PubMed Web of Science ®Google Scholar
• Ismail, R., et al., 2020. Hydrophobic ion pairing of a GLP-1 analogue for incorporating into lipid nanocarriers designed for oral delivery. European journal of pharmaceutics and biopharmaceutics, 152, 10–17.
   PubMed Web of Science ®Google Scholar
• Jain, A., et al., 2019. Thiolated polymers: pharmaceutical tool in nasal drug delivery of proteins and peptides. International journal of peptide research and therapeutics, 25 (1), 15–26.
   Web of Science ®Google Scholar
• Jallouk, A. P., et al., 2015. Modifications of natural peptides for nanoparticle and drug design. In: R. Donev, ed. Advances in protein chemistry and structural biology. Waltham, MA: Elsevier, 57–91.
   Google Scholar
• Jean, M., et al., 2011. Effective and safe gene-based delivery of GLP-1 using chitosan/plasmid-DNA therapeutic nanocomplexes in an animal model of type 2 diabetes. Gene therapy, 18 (8), 807–816.
   PubMed Web of Science ®Google Scholar
• Jin, F., Lei, B., and Wen, C., 2010. Insulin nasal powder inhalation. Patent No. US20100292141A).
   Google Scholar
• Kaplan, M., et al., 2018. Development and characterization of gels and liposomes containing ovalbumin for nasal delivery. Journal of drug delivery science and technology, 44, 108–117.
   Web of Science ®Google Scholar
• Khan, A.R., et al., 2017. Progress in brain targeting drug delivery system by nasal route. Journal of controlled release, 268, 364–389.
   PubMed Web of Science ®Google Scholar
• Khan, K., et al., 2018. Ursolic acid loaded intra nasal nano lipid vesicles for brain tumour: formulation, optimization, in-vivo brain/plasma distribution study and histopathological assessment. Biomedicine & pharmacotherapy = biomedecine & pharmacotherapie, 106, 1578–1585.
   PubMed Web of Science ®Google Scholar
• Koss, K., and Unsworth, L., 2018. Towards developing bioresponsive, self-assembled peptide materials: dynamic morphology and fractal nature of nanostructured matrices. Materials, 11 (9), 1539.
   PubMed Web of Science ®Google Scholar
• Lê, M.Q., et al., 2019. Protein delivery by porous cationic maltodextrin-based nanoparticles into nasal mucosal cells: comparison with cationic or anionic nanoparticles. International journal of pharmaceutics: X, 1, 100001.
   PubMedGoogle Scholar
• Lee, K. C., Park, C. W., and Kim, H. T., 2012. KR101112578B1 Pharmaceutical composition containing exendin for nasal administration and method for the preparation thereof.
   Google Scholar
• Lee, S.H., et al., 2011. Nano spray drying: a novel method for preparing protein nanoparticles for protein therapy. International journal of pharmaceutics, 403 (1–2), 192–200.
   PubMed Web of Science ®Google Scholar
• Lew, T.T.S., et al., 2021. Epitope-functionalized gold nanoparticles for rapid and selective detection of SARS-CoV-2 IgG antibodies. ACS nano, 15 (7), 12286–12297.
   PubMed Web of Science ®Google Scholar
• Li, H., et al., 2021. Self-assembling nanoparticle vaccines displaying the receptor binding domain of SARS-CoV-2 elicit robust protective immune responses in Rhesus monkeys. Bioconjugate chemistry, 32 (5), 1034–1046.
   PubMed Web of Science ®Google Scholar
• Li, S., et al., 2020. SARS-CoV2 mucosal immune vaccine and application thereof.
   Google Scholar
• Lin, P., et al., 2019. Phase‐changeable nanoemulsions for oral delivery of a therapeutic peptide: toward targeting the pancreas for antidiabetic treatments using lymphatic transport. Advanced functional materials, 29 (13), 1809015.
   Web of Science ®Google Scholar
• Lin, S., et al., 2019. Surface assembly of poly(I:C) on polyethyleneimine‐modified gelatin nanoparticles as immunostimulatory carriers for mucosal antigen delivery. Journal of biomedical materials research part B: Applied biomaterials, 107 (4), 1228–1237.
   PubMed Web of Science ®Google Scholar
• Majcher, M.J., et al., 2021. In situ-gelling starch nanoparticle (SNP)/O-carboxymethyl chitosan (CMCh) nanoparticle network hydrogels for the intranasal delivery of an antipsychotic peptide. Journal of controlled release, 330, 738–752.
   Google Scholar
• Maraming, P., Daduang, J., and Kah, J.C.Y., 2022. Conjugation with gold nanoparticles improves the stability of the KT2 peptide and maintains its anticancer properties. RSC advances, 12 (1), 319–325.
   Web of Science ®Google Scholar
• Marasini, N., et al., 2016. Lipid core peptide/poly(lactic-co-glycolic acid) as a highly potent intranasal vaccine delivery system against Group A streptococcus. International journal of pharmaceutics, 513 (1–2), 410–420.
   PubMed Web of Science ®Google Scholar
• Marasini, N., Skwarczynski, M., and Toth, I., 2017. Intranasal delivery of nanoparticle-based vaccines. Therapeutic delivery, 8 (3), 151–167.
   PubMed Web of Science ®Google Scholar
• Markwalter, C.E., et al., 2020. Polymeric nanocarrier formulations of biologics using inverse flash nanoprecipitation. The AAPS journal, 22 (2), 18.
   PubMed Web of Science ®Google Scholar
• Martins, D.A., et al., 2020. Effects of route of administration on oxytocin-induced changes in regional cerebral blood flow in humans. Nature communications, 11 (1), 1160.
   PubMed Web of Science ®Google Scholar
• Martins, S., et al., 2007. Lipid-based colloidal carriers for peptide and protein delivery - liposomes versus lipid nanoparticles. International journal of nanomedicine, 2 (4), 595–607.
   PubMed Web of Science ®Google Scholar
• Mas Oliva, J., et al., 2015. EP2868327A1 Nasal vaccine against the development of atherosclerosis disease and fatty liver.
   Google Scholar
• Matougui, N., et al., 2016. Lipid-based nanoformulations for peptide delivery. International journal of pharmaceutics, 502 (1-2), 80–97.
   PubMed Web of Science ®Google Scholar
• Matougui, N., et al., 2019. A comparison of different strategies for antimicrobial peptides incorporation onto/into lipid nanocapsules. Nanomedicine, 14 (13), 1647–1662.
   PubMed Web of Science ®Google Scholar
• Mentzer, B., et al., 2020. A CGRP receptor antagonist peptide formulated for nasal administration to treat migraine. Journal of pharmacy and pharmacology, 72 (10), 1352–1360.
   PubMed Web of Science ®Google Scholar
• Miwa, T., et al., 2020. Intranasal drug delivery into mouse nasal mucosa and brain utilizing arginine-rich cell-penetrating peptide-mediated protein transduction. International journal of peptide research and therapeutics, 26 (3), 1643–1650.
   Web of Science ®Google Scholar
• Mohtashamian, S., Boddohi, S., and Hosseinkhani, S., 2018. Preparation and optimization of self-assembled chondroitin sulfate-nisin nanogel based on quality by design concept. International journal of biological macromolecules, 107 (Pt B), 2730–2739.
   PubMed Web of Science ®Google Scholar
• Morita, T., and Yamahara, H., 2010. Nasal delivery systems. In: M. Morishita and K. Park, eds. Biodrug delivery systems. Boca Raton, FL: CRC Press, 120–134.
   Google Scholar
• Müller-Goymann, C. C., and Paranjpe, M., 2016. Nanodrugs in medicine and healthcare: pulmonary, nasal and ophthalmic routes, and vaccination. In: J. Cornier, A. Owen, A. Kwade, and M. van de Voorde, eds. Pharmaceutical Nanotechnology: Innovation and Production. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 633–648.
   Google Scholar
• Nakao, Y., et al., 2016. LARETH-25 and β-CD improve central transitivity and central pharmacological effect of the GLP-2 peptide. International journal of pharmaceutics, 515 (1-2), 37–45.
   PubMed Web of Science ®Google Scholar
• Natsheh, H., and Touitou, E., 2018. Phospholipid magnesome – a nasal vesicular carrier for delivery of drugs to brain. Drug delivery and translational research, 8 (3), 806–819.
   PubMed Web of Science ®Google Scholar
• Neamtu, I., et al., 2017. Basic concepts and recent advances in nanogels as carriers for medical applications. Drug delivery, 24 (1), 539–557.
   PubMed Web of Science ®Google Scholar
• Newman, S.P., Pitcairn, G.R., and Dalby, R.N., 2004. Delivery to the nasal cavity: in vitro and in vivo assessment. Critical reviews in therapeutic drug carrier systems, 21 (1), 46–66.
   Web of Science ®Google Scholar
• Nguyen, J.-T., and Kiso, Y., 2015. Delivery of peptide drugs. In: B.M. Dunn, ed. Peptide chemistry and drug design. Hoboken, NJ: John Wiley & Sons, Inc, 271–310.
   Google Scholar
• Niu, Z., et al., 2018. PEG-PGA enveloped octaarginine-peptide nanocomplexes: an oral peptide delivery strategy. Journal of controlled release, 276, 125–139.
   PubMed Web of Science ®Google Scholar
• Ozsoy, Y., Gungor, S., and Cevher, E., 2009. Nasal delivery of high molecular weight drugs. Molecules (basel, Switzerland), 14 (9), 3754–3779.
   PubMed Web of Science ®Google Scholar
• Patel, A., et al., 2014. Recent advances in protein and peptide drug delivery: a special emphasis on polymeric nanoparticles. Protein and peptide letters, 21 (11), 1102–1120.
   PubMed Web of Science ®Google Scholar
• Patil, S., et al., 2015. Role of nanotechnology in delivery of protein and peptide drugs. Current pharmaceutical design, 21 (29), 4155–4173.
   PubMed Web of Science ®Google Scholar
• Picone, P., et al., 2018. Nose-to-brain delivery of insulin enhanced by a nanogel carrier. Journal of controlled release, 270, 23–36.
   PubMed Web of Science ®Google Scholar
• Pinto Reis, C., et al., 2006. Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems. Nanomedicine: nanotechnology, biology, and medicine, 2 (2), 53–65.
   PubMed Web of Science ®Google Scholar
• Porfiryeva, N.N., et al., 2021. Mucoadhesive and mucus-penetrating interpolyelectrolyte complexes for nose-to-brain drug delivery. Nanomedicine : nanotechnology, biology, and medicine, 37, 102432.
   PubMed Web of Science ®Google Scholar
• Prasher, P., and Sharma, M., 2021. Mucoadhesive nanoformulations and their potential for combating COVID-19. Nanomedicine, 16 (28), 2497–2501.
   PubMed Web of Science ®Google Scholar
• Prego, C., Torres, D., and Alonso, M.J., 2006. Chitosan nanocapsules: a new carrier for nasal peptide delivery. Journal of drug delivery science and technology, 16 (5), 331–337.
   Web of Science ®Google Scholar
• Qiu, F., et al., 2018. Poly(propylacrylic acid)-peptide nanoplexes as a platform for enhancing the immunogenicity of neoantigen cancer vaccines. Biomaterials, 182, 82–91.
   PubMed Web of Science ®Google Scholar
• Ramvikas, M., et al., 2017. Nasal vaccine delivery. In: M. Skwarczynski and I. Toth, eds. Micro and nanotechnology in vaccine development. Oxford, UK: Elsevier, 279–301.
   Google Scholar
• Renu, S., and Renukaradhya, G.J., 2020. Chitosan nanoparticle based mucosal vaccines delivered against infectious diseases of poultry and pigs. Frontiers in bioengineering and biotechnology, 8, 558349.
   PubMed Web of Science ®Google Scholar
• Rezaei, N., et al., 2020. Encapsulation of an endostatin peptide in liposomes: stability, release, and cytotoxicity study. Colloids and surfaces B: Biointerfaces, 185, 110552.
   PubMed Web of Science ®Google Scholar
• Roesti, E.S., et al., 2020. Vaccination against amyloidogenic aggregates in pancreatic islets prevents development of type 2 diabetes mellitus. Vaccines, 8 (1), 116.
   Web of Science ®Google Scholar
• Rolando Alberto, R.-F., et al., 2020. In silico and in vivo studies of gp120-HIV-derived peptides in complex with G4-PAMAM dendrimers. RSC advances, 10 (35), 20414–20426.
   PubMed Web of Science ®Google Scholar
• Rosales-Mendoza, S., and González-Ortega, O., 2019a. Gold-based mucosal nanovaccines. In: S. Rosales-Mendoza and O. González-Ortega, eds. Nanovaccines: an innovative technology to fight human and animal diseases. Cham: Springer International Publishing, 37–60.
   Google Scholar
• Rosales-Mendoza, S., and González-Ortega, O., 2019b. Silica-based mucosal nanovaccines. In: S. Rosales-Mendoza and O. González-Ortega, eds. Nanovaccines. Cham: Springer International Publishing, 105–130.
   Google Scholar
• Sachdeva, S., 2017. Peptides as ‘drugs’: the journey so far. International journal of peptide research and therapeutics, 23 (1), 49–60.
   Web of Science ®Google Scholar
• Saeedi Saravi, S.S., and Beer, J.H., 2020. Apelin-potential therapy for COVID-19? Journal of molecular and cellular cardiology, 145, 84–87.
   PubMed Web of Science ®Google Scholar
• Saindane, N.S., Pagar, K.P., and Vavia, P.R., 2013. Nanosuspension based in situ gelling nasal spray of carvedilol: development, in vitro and in vivo characterization. AAPS PharmSciTech, 14 (1), 189–199.
   PubMed Web of Science ®Google Scholar
• Samaridou, E., and Alonso, M.J., 2018. Nose-to-brain peptide delivery - the potential of nanotechnology. Bioorganic & medicinal chemistry, 26 (10), 2888–2905.
   PubMed Web of Science ®Google Scholar
• Samaridou, E., et al., 2020. Nose-to-brain delivery of enveloped RNA - cell permeating peptide nanocomplexes for the treatment of neurodegenerative diseases. Biomaterials, 230, 119657.
   PubMed Web of Science ®Google Scholar
• Sarmento, B., Ferreira, D., and Vasconcelos, T. T., 2009. Polymer-based delivery systems for oral delivery of peptides and proteins. In: H. Jorgensen and L. Nielsen, eds. Delivery technologies for biopharmaceuticals. Chichester, UK: John Wiley & Sons, 207–226.
   Google Scholar
• Schulze, K., et al., 2017. Bivalent mucosal peptide vaccines administered using the LCP carrier system stimulate protective immune responses against Streptococcus pyogenes infection. Nanomedicine: nanotechnology, biology, and medicine, 13 (8), 2463–2474.
   PubMed Web of Science ®Google Scholar
• Shahnaz, G., et al., 2012. Thiolated chitosan nanoparticles for the nasal administration of leuprolide: bioavailability and pharmacokinetic characterization. International journal of pharmaceutics, 428 (1–2), 164–170.
   PubMed Web of Science ®Google Scholar
• Si, Y., et al., 2018. Intranasal delivery of adjuvant-free peptide nanofibers elicits resident CD8+ T cell responses. Journal of controlled release, 282, 120–130.
   PubMed Web of Science ®Google Scholar
• Simon, M., et al., 2005. Insulin containing nanocomplexes formed by self-assembly from biodegradable amine-modified poly(vinyl alcohol)-graft-poly(l-lactide): bioavailability and nasal tolerability in rats. Pharmaceutical research, 22 (11), 1879–1886.
   PubMed Web of Science ®Google Scholar
• Sintov, A.C., Levy, H. v., and Botner, S., 2010. Systemic delivery of insulin via the nasal route using a new microemulsion system: in vitro and in vivo studies. Journal of controlled release, 148 (2), 168–176.
   PubMed Web of Science ®Google Scholar
• Sonvico, F., et al., 2018. Surface-modified nanocarriers for nose-to-brain delivery: from bioadhesion to targeting. Pharmaceutics, 10 (1), 34.
   PubMed Web of Science ®Google Scholar
• Sosnik, A., 2016. Tissue-based in vitro and ex vivo models for nasal permeability studies. In: B. Sarmento, ed. Concepts and models for drug permeability studies. Cambridge, UK: Elsevier, 237–254.
   Google Scholar
• Sun, H., et al., 2020. Use of palmitate modified IKVAV in preparation of vaccine T-cell epitope peptide coupling agent and in preparation of anti-tumor nanoemulsion adjuvant nasal mucosal vaccine.
   Google Scholar
• Sung, H., Liang, H.-F., and Tu, H., 2011. US7871990B1 Nanoparticles for protein drug delivery.
   Google Scholar
• Mak, T.W., Saunders, M.E., and Jett, B.D.B.T., 2014. Mucosal and cutaneous immunity. In: T.W. Mak, M.E. Saunders, and B.D.B.T. Jett, eds. Primer to the immune response. Boston, MA: Elsevier, 269–292.
   Google Scholar
• Takeuchi, H., et al., 2020. Nasal vaccine delivery attenuates brain pathology and cognitive impairment in tauopathy model mice. NPJ vaccines, 5 (1), 28.
   PubMed Web of Science ®Google Scholar
• Tanaka, N., et al., 2020. Development of a brain-permeable peptide nanofiber that prevents aggregation of Alzheimer pathogenic proteins. PLOS one, 15 (7), e0235979.
   PubMed Web of Science ®Google Scholar
• Tang, C., et al., 2017. An innovative method for preparation of hydrophobic ion-pairing colistin entrapped poly(lactic acid) nanoparticles: loading and release mechanism study. European journal of pharmaceutical sciences, 102, 63–70.
   PubMed Web of Science ®Google Scholar
• Teekamp, N., et al., 2015. Production methods and stabilization strategies for polymer-based nanoparticles and microparticles for parenteral delivery of peptides and proteins. Expert opinion on drug delivery, 12 (8), 1311–1331.
   PubMed Web of Science ®Google Scholar
• Thwala, L.N., et al., 2016. The interaction of protamine nanocapsules with the intestinal epithelium: a mechanistic approach. Journal of controlled release, 243, 109–120.
   PubMed Web of Science ®Google Scholar
• Tomono, T., et al., 2020. Nasal absorption enhancement of protein drugs independent to their chemical properties in the presence of hyaluronic acid modified with tetraglycine-L-octaarginine. European journal of pharmaceutics and biopharmaceutics, 154, 186–194.
   PubMed Web of Science ®Google Scholar
• Tripathi, S., et al., 2021. Nano-lipidic formulation and therapeutic strategies for Alzheimer's disease via intranasal route. Journal of microencapsulation, 38 (7–8), 572–593.
   PubMed Web of Science ®Google Scholar
• Uhlig, T., et al., 2014. The emergence of peptides in the pharmaceutical business: from exploration to exploitation. EuPA open proteomics, 4, 58–69.
   Google Scholar
• van der Walle, C. F., and Olejnik, O., 2011. An overview of the field of peptide and protein delivery. In: C. van der Walle, ed. Peptide and protein delivery. Boston, MA: Elsevier, 1–22.
   Google Scholar
• Vauthier, C., 2016. Polymer nanoparticles for in vivo applications: progress on preparation methods and future challenges. In: C. Vauthier and G. Ponchel, eds. Polymer nanoparticles for nanomedicines. Cham (CH): Springer, 3–16.
   Google Scholar
• Verified Market Research, 2021. Global peptide therapeutics market size by application, by route of administration, by synthesis technology, by geographic scope and forecast [online]. Available from: https://www.verifiedmarketresearch.com/product/peptide-therapeutics-market/ [Accessed 2 Mar 2021].
   Google Scholar
• Vo, T. P., et al., 2015. Emerging trends in delivery of novel vaccine formulations. In: M.J. D'Souza, ed. Nanoparticulate vaccine delivery systems. 1st ed. New York, NY: Jenny Stanford Publishing.
   Google Scholar
• Wang, W., and Roberts, C. J., 2010. Aggregation of therapeutic proteins. Aggregation of therapeutic proteins. Hoboken, NJ: John Wiley & Sons.
   Google Scholar
• Wang, Y., et al., 2014. Mucoadhesive and enzymatic inhibitory nanoparticles for transnasal insulin delivery. Nanomedicine, 9 (4), 451–464.
   PubMed Web of Science ®Google Scholar
• Whateley, T.L., 2002. Drug delivery and targeting; for pharmacists and pharmaceutical scientists. Journal of drug targeting, 10 (8), 637–637.
   Google Scholar
• World Health Organization, 2021. COVID-19 vaccine tracker and landscape (Landscape of novel coronavirus candidate vaccine development worldwide). Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
   Google Scholar
• Wright, J., 2007. Overview of protein formulation and delivery. In: E. McNally and J.E. Hastedt, eds. Protein formulation and delivery. Boca Raton, FL: CRC Press, 19–24.
   Google Scholar
• Yang, Y., et al., 2019. Epitope-loaded nanoemulsion delivery system with ability of extending antigen release elicits potent Th1 response for intranasal vaccine against Helicobacter pylori. Journal of nanobiotechnology, 17 (1), 6.
   PubMed Web of Science ®Google Scholar
• Yang, Y., et al., 2021. A novel self-assembled epitope peptide nanoemulsion vaccine targeting nasal mucosal epithelial cell for reinvigorating CD8+ T cell immune activity and inhibiting tumor progression. International journal of biological macromolecules, 183, 1891–1902.
   PubMed Web of Science ®Google Scholar
• Ye, C., and Venkatraman, S., 2019. The long-term delivery of proteins and peptides using micro/nanoparticles: overview and perspectives. Therapeutic delivery, 10 (5), 269–272.
   PubMed Web of Science ®Google Scholar
• Yeomans, D. C., Carson, D., and Thirucote, R., 2021. AU2020286221A1 Magnesium-containing oxytocin formulations and methods of use.
   Google Scholar
• Yordanova, Y., et al., 2018. Zn2+-triggered self-assembly of gonadorelin [6-D-Phe] to produce nanostructures and fibrils. Scientific reports, 8 (1), 11280.
   PubMed Web of Science ®Google Scholar
• Yu, S., et al., 2019. Chitosan and chitosan coating nanoparticles for the treatment of brain disease. International journal of pharmaceutics, 560, 282–293.
   PubMed Web of Science ®Google Scholar
• Yuan, H., et al., 2009. Strategic approaches for improving entrapment of hydrophilic peptide drugs by lipid nanoparticles. Colloids and surfaces. B, biointerfaces, 70 (2), 248–253.
   PubMed Web of Science ®Google Scholar
• Yuba, E., and Kono, K., 2014. Nasal delivery of biopharmaceuticals. In: J. das Neves and B. Sarmento, eds. Mucosal delivery of biopharmaceuticals. Boston, MA: Springer, 197–220.
   Google Scholar
• Zada, M.H., et al., 2019. Dispersible hydrolytically sensitive nanoparticles for nasal delivery of thyrotropin releasing hormone (TRH). Journal of controlled release, 295, 278–289.
   PubMed Web of Science ®Google Scholar
• Zheng, C., et al., 2013. Amphiphilic glycopolymer nanoparticles as vehicles for nasal delivery of peptides and proteins. European journal of pharmaceutical sciences, 49 (4), 474–482.
   PubMed Web of Science ®Google Scholar
• Zhou, X.-R., et al., 2017. Self-assembly nanostructure controlled sustained release, activity and stability of peptide drugs. International journal of pharmaceutics, 528 (1–2), 723–731.
   PubMed Web of Science ®Google Scholar
• Zuglianello, C., et al., 2021. Dextran sulfate/pramlintide polyelectrolyte nanoparticles as a promising delivery system: optimization, evaluation of supramolecular interactions and effect on conformational stability of the peptide drug. Journal of the Brazilian chemical society, 32 (8), 1642–1653.
   Google Scholar